Augurex is pleased to announce the launch of JOINTstat (14-3-3ƞ) testing services through Dynacare, one of Canada’s largest and most established health solution companies with a dedicated mission to support healthy lives with commitment and care. This arrangement will make JOINTstat testing accessible to more patients and physicians across Canada.
JOINTstat, a biomarker blood test, provides transformational insights into autoimmune joint damage
mechanisms and the clinical management of rheumatoid arthritis (RA). The highest priority in
rheumatology care is to identify patients early, for prompt intervention and tight treatment control,
drastically improving outcomes.
There is increasing momentum to investigate the role of 14-3-3ƞ in various autoimmune diseases with
joint involvement, and through Dynacare, access to 14-3-3η testing services by investigators in the
Canadian pharmaceutical industry, will also be enabled. JOINTstat measures the 14-3-3ƞ (eta) protein in
blood and informs mechanistic joint damage processes allowing biochemical pathways and therapeutic
options to be investigated from the basic science level, right through to disease prevention and
controlled clinical remission